AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast Cancer
Advanced Science · 2025-05 · 12 (17)
DOI: 10.1002/advs.202408106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.02.2025. Verfasst von Zicheng Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, 510000, …. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-akt, Copper, Ferredoxins. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Joint Funding Project of Guangzhou, Guangxi Natural Science Foundation.
Abstract (Originalsprache)
Cuproptosis, a recently defined copper‐dependent cell death pathway, remains largely unexplored in tumor therapies, particularly in breast cancer. This study demonstrates that triple‐negative breast cancer (TNBC) bears a relatively elevated copper levels and exhibits resistance to cuproptosis. Mechanistically, copper activates the AKT signaling pathway, which inhibits ferredoxin‐1 (FDX1), a key regulator of cuproptosis. AKT1‐mediated FDX1 phosphorylation not only abrogates FDX1‐induced cuproptosis and aerobic respiration but also promotes glycolysis. Consequently, the combination of AKT1 inhibitors and the copper ionophores synergistically alleviate TNBC tumorigenesis both in vitro and in vivo. In summary, the findings reveal a crucial mechanism underlying TNBC resistance to cuproptosis and suggest a potential therapeutic approach for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, 510000, China.
- Department of Breast and Thyroid Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Guangxi, Guangxi, 533000, China.
- Department of Breast Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510000, China.
- Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510000, China.
ORCID-Profile: Jie Li
Förderung
- National Natural Science Foundation of China
- Joint Funding Project of Guangzhou
- Guangxi Natural Science Foundation
- Affiliated Hospital of Youjiang Medical University for Nationalities
- ProteomeXchange under the accession
- Natural Science Foundation of Guangxi Province
Zitieren
APA
Sun, Z., Xu, H., Lu, G., Yang, C., Gao, X., Zhang, J., Liu, X., Chen, Y., Wang, K., Guo, J., & Li, J. (2025). AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast Cancer. Advanced Science, 12(17). https://doi.org/10.1002/advs.202408106
Vancouver
Sun Z, Xu H, Lu G, Yang C, Gao X, Zhang J, et al. AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2025;12(17). doi:10.1002/advs.202408106
BibTeX
@article{Sun2025,
author = {Sun, Zicheng and Xu, Huazhen and Lu, Guanming and Yang, Ciqiu and Gao, Xinya and Zhang, Jing and Liu, Xin and Chen, Yongcheng and Wang, Kun and Guo, Jianping and Li, Jie},
title = {AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {17},
doi = {10.1002/advs.202408106}
}
EUVIMED